Talabostat Withdrawn Phase 2 Trials for Renal Cancers Treatment

IndicationsStatusPurposePhase
WithdrawnTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00489710Talabostat in Treating Patients With Metastatic Kidney Cancer